APGE · As filed with the SEC
Apogee Therapeutics balance sheet, by quarter
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 105,571,000 | 451,797,000 | 131,549,000 | 107,914,000 |
| Marketable securities | 866,355,000 | 608,088,000 | 598,643,000 | 419,375,000 |
| Prepaid expenses and other current assets | 19,807,000 | 13,912,000 | 11,166,000 | 12,808,000 |
| Total current assets | 991,733,000 | 1,073,797,000 | 741,358,000 | 540,097,000 |
| Long-term marketable securities | 321,943,000 | 198,354,000 | 172,730,000 | 61,640,000 |
| Property and equipment, net | 4,822,000 | 5,280,000 | 5,688,000 | 6,032,000 |
| Right-of-use asset, net | 6,708,000 | 7,707,000 | 8,687,000 | 9,646,000 |
| Other non-current assets | 10,607,000 | 8,516,000 | 8,671,000 | 8,744,000 |
| Total assets | 1,335,813,000 | 1,293,654,000 | 937,134,000 | 626,159,000 |
| Liabilities and stockholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable | 3,080,000 | 1,237,000 | 1,221,000 | 376,000 |
| Lease liability | 2,365,000 | 3,138,000 | 3,504,000 | 4,079,000 |
| Accrued expenses and other current liabilities | 32,065,000 | 28,577,000 | 23,181,000 | 29,592,000 |
| Total current liabilities | 37,510,000 | 32,952,000 | 27,906,000 | 34,047,000 |
| Long-term liabilities: | ||||
| Lease liability, net of current | 4,468,000 | 4,909,000 | 5,345,000 | 5,774,000 |
| Revenue share liability | 99,231,000 | — | — | — |
| Total liabilities | 141,209,000 | 37,861,000 | 33,251,000 | 39,821,000 |
| Stockholders' equity: | ||||
| Common Stock; $0.00001 par value, 400,000,000 authorized, 75,611,894 issued and 75,339,499 outstanding as of June 30, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 2025 | 1,000 | 1,000 | 1,000 | 1,000 |
| Additional paid-in capital | 1,918,830,000 | 1,892,411,000 | 1,464,561,000 | 1,077,681,000 |
| Accumulated other comprehensive (loss) income | (2,503,000) | (749,000) | 1,080,000 | 1,028,000 |
| Accumulated deficit | (721,724,000) | (635,870,000) | (561,759,000) | (492,372,000) |
| Total stockholders' equity | 1,194,604,000 | 1,255,793,000 | 903,883,000 | 586,338,000 |
| Total liabilities and stockholders' equity | 1,335,813,000 | 1,293,654,000 | 937,134,000 | 626,159,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.